Plasma MiR-6089 As Potential Diagnostic Biomarker for Retinoblastoma

Overview

Journal Int Ophthalmol

Specialty Ophthalmology

Date 2021 Mar 27

PMID 33772700

Citations 1

Authors

Xiu-Hong Li

An-Jie Shi

Jia Li

Hong-Feng Yuan

Affiliations

Soon will be listed here.

Abstract

Objective: The purpose of this study was to screen target miRNA related to RB and explore the expression levels of target miRNA in RB and its potential value of diagnosis.

Methods: The Affymetrix GeneChip miRNA 4.0 Array was used to screen the differential miRNAs in the plasma of 5 RB patients before and after intravenous chemotherapy, and the most significant down-regulated miRNA was selected for target miRNA. Quantitative reverse transcription-polymerase chain reaction (qRT-PCR) is used to verify the expression levels of plasma target miRNA in 30 RB patients. Then, qRT-PCR was performed to further verify the expression of target miRNA in plasma of RB patients and RB tumor tissues. Finally, receiver-operating-characteristic (ROC) curve and the area under the ROC curve (AUC) were used to evaluate the diagnostic power of plasma target miRNA.

Results: The miRNA Array obtain 8 core miRNAs, 1 up-regulated and 7 down-regulated, of which miR-6089 was the most significantly down-regulated. Plasma miR-6089 levels were significantly up-regulated in RB patients. Besides, in RB tumor tissues, miR-6089 levels were also obviously up-regulated. After intravenous chemotherapy, the expression of plasma miR-6089 was significantly decreased. Furthermore, ROC curve analysis showed that miR-6089 in the plasma had a good sensitivity and specificity for distinguishing RB from the healthy control group.

Conclusions: MiR-6089 may be considered as a novel potential diagnostic biomarker for RB.

Trial Registration Number: ChiCTR2000040154; date of registration: 2020/11/22; retrospectively registered.

Citing Articles

More than the SRY: The Non-Coding Landscape of the Y Chromosome and Its Importance in Human Disease.

Westemeier-Rice E, Winters M, Rawson T, Martinez I Noncoding RNA. 2024; 10(2).

PMID: 38668379 PMC: 11054740. DOI: 10.3390/ncrna10020021.

References

Kivela T . The epidemiological challenge of the most frequent eye cancer: retinoblastoma, an issue of birth and death. Br J Ophthalmol. 2009; 93(9):1129-31. DOI: 10.1136/bjo.2008.150292. View

Theriault B, Dimaras H, Gallie B, Corson T . The genomic landscape of retinoblastoma: a review. Clin Exp Ophthalmol. 2014; 42(1):33-52. PMC: 3896868. DOI: 10.1111/ceo.12132. View

Mehta M, Sethi S, Pushker N, Kashyap S, Sen S, Bajaj M . Retinoblastoma. Singapore Med J. 2012; 53(2):128-35. View

Wu W, Sun M, Zou G, Chen J . MicroRNA and cancer: Current status and prospective. Int J Cancer. 2006; 120(5):953-60. DOI: 10.1002/ijc.22454. View

Krol J, Loedige I, Filipowicz W . The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet. 2010; 11(9):597-610. DOI: 10.1038/nrg2843. View

Eulalio A, Huntzinger E, Izaurralde E . Getting to the root of miRNA-mediated gene silencing. Cell. 2008; 132(1):9-14. DOI: 10.1016/j.cell.2007.12.024. View

Zhang H, Zhu M, Shan X, Zhou X, Wang T, Zhang J . A panel of seven-miRNA signature in plasma as potential biomarker for colorectal cancer diagnosis. Gene. 2018; 687:246-254. DOI: 10.1016/j.gene.2018.11.055. View

Pan J, Zhou C, Zhao X, He J, Tian H, Shen W . A two-miRNA signature (miR-33a-5p and miR-128-3p) in whole blood as potential biomarker for early diagnosis of lung cancer. Sci Rep. 2018; 8(1):16699. PMC: 6232109. DOI: 10.1038/s41598-018-35139-3. View

Gholamin S, Pasdar A, Khorrami M, Mirzaei H, Mirzaei H, Salehi R . The potential for circulating microRNAs in the diagnosis of myocardial infarction: a novel approach to disease diagnosis and treatment. Curr Pharm Des. 2015; 22(3):397-403. DOI: 10.2174/1381612822666151112151924. View

10.

Shin V, Ng E, Chan V, Kwong A, Chu K . A three-miRNA signature as promising non-invasive diagnostic marker for gastric cancer. Mol Cancer. 2015; 14:202. PMC: 4659169. DOI: 10.1186/s12943-015-0473-3. View

11.

Liu S, Wang Y, Sun Y, Miao L, Wang J, Li Y . Plasma microRNA-320, microRNA-let-7e and microRNA-21 as novel potential biomarkers for the detection of retinoblastoma. Biomed Rep. 2014; 2(3):424-428. PMC: 3990201. DOI: 10.3892/br.2014.246. View

12.

Zhou P, Li X . Serum miR-338-5p has potential for use as a tumor marker for retinoblastoma. Oncol Lett. 2019; 18(1):307-313. PMC: 6540340. DOI: 10.3892/ol.2019.10331. View

13.

Yang K, Wang S, Cheng Y, Tian Y, Hou J . Role of miRNA-21 in the diagnosis and prediction of treatment efficacy of primary central nervous system lymphoma. Oncol Lett. 2019; 17(3):3475-3481. PMC: 6396200. DOI: 10.3892/ol.2019.9941. View

14.

Heneghan H, Miller N, Kelly R, Newell J, Kerin M . Systemic miRNA-195 differentiates breast cancer from other malignancies and is a potential biomarker for detecting noninvasive and early stage disease. Oncologist. 2010; 15(7):673-82. PMC: 3228012. DOI: 10.1634/theoncologist.2010-0103. View

15.

Zhou X, Huang Z, Xu L, Zhu M, Zhang L, Zhang H . A panel of 13-miRNA signature as a potential biomarker for predicting survival in pancreatic cancer. Oncotarget. 2016; 7(43):69616-69624. PMC: 5342502. DOI: 10.18632/oncotarget.11903. View

16.

Abu-Duhier F, Javid J, Sughayer M, Mir R, Albalawi T, Alauddin M . Clinical Significance of Circulatory miRNA-21 as an Efficient Non-Invasive Biomarker for the Screening of Lung Cancer Patients. Asian Pac J Cancer Prev. 2018; 19(9):2607-2611. PMC: 6249464. DOI: 10.22034/APJCP.2018.19.9.2607. View

17.

Konishi H, Ichikawa D, Komatsu S, Shiozaki A, Tsujiura M, Takeshita H . Detection of gastric cancer-associated microRNAs on microRNA microarray comparing pre- and post-operative plasma. Br J Cancer. 2012; 106(4):740-7. PMC: 3322946. DOI: 10.1038/bjc.2011.588. View

18.

Balzano F, Deiana M, Dei Giudici S, Oggiano A, Baralla A, Pasella S . miRNA Stability in Frozen Plasma Samples. Molecules. 2015; 20(10):19030-40. PMC: 6331950. DOI: 10.3390/molecules201019030. View

19.

Tsujiura M, Ichikawa D, Komatsu S, Shiozaki A, Takeshita H, Kosuga T . Circulating microRNAs in plasma of patients with gastric cancers. Br J Cancer. 2010; 102(7):1174-9. PMC: 2853097. DOI: 10.1038/sj.bjc.6605608. View

20.

Qiu X, Zhang J, Shi W, Liu S, Kang M, Chu H . Circulating MicroRNA-26a in Plasma and Its Potential Diagnostic Value in Gastric Cancer. PLoS One. 2016; 11(3):e0151345. PMC: 4806920. DOI: 10.1371/journal.pone.0151345. View